BCL2 and lymphoma: Among these, activated B-cell-like (ABC) subtype, double expressor lymphoma (DEL, double expression of the MYC and BCL2 oncogenes), and double- or triple-hit lymphomas (DH/THLs, genetic rearrangements of MYC and BCL2 and/or BCL6) have been proven to obtain adverse clinical outcomes (2).